dacarbazine

Also known as 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 5-(dimethyltriazeno)imidazole-4-carboxamide, 4-(dimethyltriazeno)imidazole-5-carboxamide, 5-(3,3-dimethyltriazeno)imidazole-4-carboxamide, 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide, (E)-dacarbazine

Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's lymphoma, it is often used together with vinblastine, bleomycin, and doxorubicin. It is given by injection into a vein.

Chemical data

Formula: C6H10N6O
Molecular weight: 182.18 g/mol
IUPAC name: 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
SMILES: CN(C)/N=N/C1=C(NC=N1)C(=O)N
InChIKey: FDKXTQMXEQVLRF-ZHACJKMWSA-N
XLogP: -0.6
Polar surface area: 99.7 Å²
H-bond donors: 2
H-bond acceptors: 5
Formal charge: 0

via PubChem

Research

12,343 papers

Dacarbazine.

~3 min read

Article

7 sections

Contents

Medical uses
Side effects
Mechanism of action
Synthesis
History
Society and culture
References

Common side effects include loss of appetite, vomiting, low white blood cell count, and low platelets. Other serious side effects include liver problems and allergic reactions. It is unclear if use in pregnancy is safe for the baby. Dacarbazine is in the alkylating agent and purine analog families of medication.